
|Videos|April 6, 2016
How Renal Function and Comorbidities Affect Dosing for NOACs
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient's renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
Advertisement
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient’s renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1s and Muscle Loss: The Conversation Pharmacists Are Not Having, But Should Be
2
AHA/ACC CKM Guideline Formally Endorses GLP-1 Therapies for Kidney, Heart Protection
3
Ammoxetine: Emerging Data from a Phase 2 Antidepressant Trial
4
McKesson ideaShare 2026: Building Specialty and Infusion Capacity From the Ground Up
5





















































































































